Review

Covid-19 pandemic and the skin

Kossara Drenovska¹, MD, PhD, Enno Schmidt²,³, MD, PhD and Snejina Vassileva¹, MD, PhD

¹Department of Dermatology and Venereology, University Hospital “Alexandrovska”, Medical University – Sofia, Sofia, Bulgaria, ²Department of Dermatology, University of Lübeck, Lübeck, Germany, and ³Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany

Abstract

In the beginning of the COVID-19 outbreak, skin manifestations, if present, were not paid enough attention. Then, the focus moved toward the impact of the prolonged use of personal protective measures in both healthcare workers and patients. In the meantime, attention is increasingly paid to dermatology as a result of the concern for certain groups of dermatologic patients, including those whose condition may worsen by the thorough disinfection measures and those treated with immunosuppressants or immunomodulators. Following patients with psoriasis on biological therapy, as well as other inflammatory and autoimmune cutaneous disorders such as atopic dermatitis, pemphigus, pemphigoid diseases, and skin cancer provoked the interest of dermatologists. Finally, an intriguing question to the dermatologic society was whether skin changes during COVID-19 infection exist and what could be their diagnostic or prognostic value. Here, we summarize skin conditions during the COVID-19 pandemic, patient information, and expert recommendations and give an overview about the registries launched to document skin changes during COVID-19, as well as details about certain patient groups infected with SARS-CoV-2, for example, psoriasis, atopic dermatitis, and autoimmune bullous diseases.

Introduction

The current coronavirus disease (COVID-19) manifests itself predominantly as a disorder of the lower respiratory tract leading to pneumonia. It spreads through droplets, aerosols, and contact surfaces and causes fever, fatigue, dry cough, and subsequent shortness of breath.¹ Headache, myalgia, arthralgia, and gastrointestinal symptoms may occur in 5–15% of patients.²

In the very beginning of the COVID-19 outbreak, data on skin manifestations were scarce. The first look toward dermatology focused on the prevention of the skin and mucous membranes from contact with the infection. Chinese dermatologists were the first to publish a consensus on the adequate measures for
topical disinfection in the new pandemic situation.³ Wearing protective masks, goggles, and gloves, thorough hand washing, as well as frequent use of topical antiseptics became obligatory for a broad spectrum of the population and medical staff. Very soon this resulted in occupational skin damage among medical specialists including facial skin injury on the back of the nose, forehead, and suprazygomatic area.⁴,⁵ Additionally, damage of the skin barrier through aggressive disinfection or wearing gloves could be considered a prerequisite for provoking or exacerbating of contact or atopic dermatitis, chronic hand eczema, skin candidiasis, etc.

**Expert recommendations and patient information during COVID-19**

The second wave of COVID-19-related dermatological publications was provoked by the concern to all patients with severe dermatological diseases who undergo treatment with biological agents or other types of immunosuppressive or immunomodulatory therapies.⁶–⁸ Psoriasis vulgaris treated with biologics has already been reported to exacerbate from various infectious diseases like zika and dengue virus.⁹ Psoriasis was the first dermatosis during the COVID-19 pandemic that drew the attention of dermatologists owing to the wide scope of cytotoxic or biological agents used for its treatment.¹⁰ Patients with hidradenitis suppurativa or other rare diseases who probably face similar problems were provided information on the necessary preventive measures and optional treatment regimens by the European Reference Networks (ERN).¹² Atopic dermatitis patients who demonstrate elevated level of respiratory comorbidities were advised by the European Academy of Dermatology and Venereology (EADV) task force on atopic dermatitis not to modify by themselves previously stable immune-modulating or immunosuppressive therapies because of increased risk of relapses.¹³ Patients with autoimmune bullous dermatoses, especially those suffering from pemphigus and mucous membrane pemphigoid, were informed by the respective AIBD task force on the effects of systemic corticosteroids, steroid-sparing agents, rituximab, and other treatment options during the COVID-19 pandemic.¹⁴,¹⁵ Patients with connective tissue diseases on disease-modifying antirheumatic drugs, biologics, or other immunosuppressive medications were advised to consult their rheumatologist and stop these drugs during an infection, while noninfected patients are required to continue their medication during the epidemic.¹⁶ Expert consensus-based guidance was elaborated on the use of systemic immunosuppressive therapies for inflammatory skin diseases in children during COVID-19 infection along with recommendations concerning the management of infantile hemangiomata.¹⁷,¹⁸ In the meanwhile, dermatologic surgeons and dermatoscopyists alarmed on the possible delay and risk of complications in diagnosing and treatment of non-melanoma skin cancer, melanoma, and lymphoma.¹⁹,²⁰ Reorganization of the work in dermatology units was proposed for maximum safety of both patients and staff.²¹–²⁹ Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) took place among the streptococcal infections, varicella, measles, hepatitis B and C, and AIDS with which dermatologists are often in contact.³⁰ Patient recommendations and guidelines on specific dermatological conditions during the COVID-19 pandemic are detailed in Table 1.

**Skin manifestations during COVID-19 disease**

The most intriguing question to all dermatologists was whether specific skin manifestations of COVID-19 exist. A look back to previous coronavirus infections found only sporadic reports on coronavirus NL63-related acute hemorrhagic edema of infancy (AHEI), a rare form of leukocytoclastic vasculitis of early childhood.³¹ Another etiologic study with a panel of respiratory viruses in 58 children with petechial rash has detected 2 human coronavirus (HoCV) positive samples of 39 virus-positive children.³²

Cutaneous involvement during the COVID-19 disease was estimated to be 0.2% in China where only two patients of 1,099 with confirmed SARS-CoV-2 infection presented with “skin rash” without further characteristics.² In Italy, the range of reported skin manifestations reached 20.4%, given that 18 of 88 COVID-19 patients had it. They presented with erythematous rash (14 patients), widespread urticarial lesions (three patients), and chickenpox-like vesicles (one patient). The lesions were asymptomatic or slightly pruritic and affected mainly the trunk. They appeared at the onset of the infection or in the course of hospitalization and were healing within a few days. As no correlation with the disease severity was found, a nonspecific character was presumed.³³ In a French prospective study on the incidence and types of COVID-19-associated cutaneous manifestations, skin involvement was reported in only 4.9% (five patients of 103) and presented as erythematous rash (two patients) and urticaria (two patients). Lesions appeared during the illness or the prodromal phase, affected mainly the face and upper part of the body, were pruritic, and resolved between 24 hours and 6 days. The authors concluded that cutaneous manifestations of COVID-19 were unusual and mostly nonspecific.³⁴ These initial data were followed by a growing number of individual reports and case series.

**Erythematous rashes**

Morbilliform rash as a presenting symptom of COVID-19 was reported in a 20-year-old previously healthy man from the USA. Extensive maculopapular and nonpruritic lesions on the trunk and extremities were consistent with viral exanthema. The patient demonstrated both positive SARS-CoV-2 polymerase chain reaction (PCR) test and bilateral multifocal pneumonia on chest radiograph.³⁵ Asymptomatic malar edema and slight edema were described in another 26-year-old man from the USA who was treated with adalimumab 40 mg biweekly for
Spain. Skin lesions appeared 6 days after the onset of drug intake and viral infection, primarily parvovirus B19. It was considered in the differential diagnosis of SDRIFE has previously been associated with both paracetamol discontinuation. Relation to the infection was disputed.

The rash resolved within 5 days without paracetamol intake. A biopsy was not performed, but the skin changes could be related to the viral infection or patient’s immune response.

Crohn’s disease in remission. This patient was not tested, but his condition followed a contact with SARS-CoV-2-infected persons. The skin eruption was preceded by general symptoms of infection and resolved within 20 days. It was considered a typical viral exanthema with a possible clinical modification by the adalimumab treatment, the latter being on hold until the patient’s full recovery.

Nonmelanoma skin cancer, melanoma, and lymphoma

Management of dermatological practice

Table 1 Patient information and expert recommendations on dermatological conditions during the COVID-19 pandemic

| Dermatological condition | Patient information                                                                 | Expert recommendation                      |
|--------------------------|-------------------------------------------------------------------------------------|---------------------------------------------|
| Severe skin diseases on biological or immunomodulation therapy | https://www.nice.org.uk/guidance/ng169 http://www.bad.org.uk/healthcare-professionals/covid-19 | NICE guideline\(^6\)                             |
| Psoriasis vulgaris       | https://www.eadv.org/covid-19/task-force https://www.pсорiasiscouncil.org/blog/Statement-on-COVID-19-and-Psoriasis.htm | BDRM advice for dermatology HCPs\(^7\)   |
| Hidradenitis suppurativa and other rare skin diseases | https://ern-skin.eu/covid-19/ https://www.eadv.org/covid-19/task-force | Conforti et al.\(^10\)                             |
| Atopic dermatitis        | https://www.eadv.org/covid-19/task-force | Lebowohl et al.\(^11\)                             |
| Autoimmune blistering diseases | http://www.pemphigus.org/information-for-pemphigus-and-pemphigoid-patients-related-to-coronavirus-disease-covid-19/ | Bodemer et al.\(^12\)                             |
| Rheumatologic skin diseases | https://www.rheumatology.org.uk/news-policy/details/Covid19-Coronavirus-update-members https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-Patients-with-Rheumatic-Diseases.pdf | Arora et al.\(^17\)                             |
| Inflammatory skin diseases in children | https://pedisderm.net/resources/general-information-for-patients-and-caregivers-about-covid-19/ | Reynolds et al.\(^18\)                             |
| Infantile hemangiomas    | https://doi.org/10.1111/pde.14196 | Frieden et al.\(^20\)                             |
| Nonmelanoma skin cancer, melanoma, and lymphoma | https://www.nccn.org/covid-19/default.aspx https://www.skincancer.org/treatment-resources/support-resources/robins-nest/covid-19-and-you https://www.rcr.ac.uk/sites/default/files/non-melanoma-skin-cancer-covid19.pdf https://www.rcr.ac.uk/sites/default/files/melanoma-treatment-covid19.pdf https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/melanoma-in-the-covid-19-era | Der Sarkissian et al.\(^21\)                             |
| Management of dermatological practice | https://www.aad.org/member/practice/managing/coronavirus | Zic JA et al.\(^26\)                             |

| Vesiculobullous rashes | Varicella-like papulovesicular exanthema was reported in a series of 22 patients from Italy as a rare but specific cutaneous manifestation of COVID-19. The rash developed on average within 3 days after systemic symptoms and affected mostly men with median age of 60 years. Lesions predominantly affected the trunk, and mild itching was reported in 40% of the cases. | NICE guideline\(^6\) |
patients. Histology was consistent with viral infection. The lesions regressed within 8 days without scarring. Another prospective observational study from Spain including 24 patients with COVID-19-related vesicular rashes suggested two presentation patterns, diffuse and localized, respectively. The diffuse pattern was polymorphic, widespread, and resembling hand-foot-mouth disease, while the localized was monomorphic, involving mostly the trunk, and resembling chickenpox. In this series, COVID-19 vesicular rashes also developed mostly after the onset of typical COVID-19 symptoms. Their histological presentation was consistent with viral infection. PCR tests failed to detect SARS-CoV-2 inside the vesicles so the direct relation to presentation was consistent with viral infection. The induced thrombotic events were caused by endothelial damage and vascular disorders was suspected, and vasculitis-like changes were histologically confirmed. A new type of COVID-19-related vasculitis was suggested based on the large number of similar cases from Italy and France. Secondary microthrombosis caused by endothelial damage and vascular disorders was suspected, and vasculitis-like changes were histologically confirmed. Lupus erythematosus (LE)-like chilblains of the feet associated with changes as a result of early interferon (IFN)-I response. 

Acral ischemia and chilblain-like rashes

Acral ischemia was initially observed in isolated cases of young and otherwise healthy individuals who presented with occasionally itchy or burning erythematous bluish macules or papules on solitary digits. Some of the patients remained healthy although SARS-CoV-2 positive, while others developed general symptoms of infection. A new type of COVID-19-related vasculitis was suggested based on the large number of similar cases from Italy and France. Secondary microthrombosis caused by endothelial damage and vascular disorders was suspected, and vasculitis-like changes were histologically confirmed. Lupus erythematosus (LE)-like chilblains of the feet associated with normal coagulation status were explained with microangiopathic changes as a result of early interferon (IFN)-I response. “Covid toes” was the term introduced recently for these pernio-like lesions in the absence of previous exposure to cold temperatures. Chilblain-like lesions (CCL) “outbreak” was detected in Italy in a series of 63 otherwise healthy adolescents with occasional history of initial general symptoms. Cutaneous lesions were painful or itchy, stable, and mostly affected toes and soles in two different patterns; erythematous-edematous and blistering type. Despite the low rate of laboratory-proven SARS-CoV-2 infection, the authors supported the hypothesis of a delayed immune-mediated reaction to the virus in genetically predisposed patients. A retrospective nationwide study in France including 277 outpatients with median age 27 years (range 2–98 years) also detected high predominance of acral changes (n = 142, 80%) presenting mainly as CCL (n = 106/142, 75%). Among the 277 patients, 34 had a SARS-CoV2 PCR test, of which 25 were positive (74%). Seven of these 25 (28%) had acral lesions. Additionally, 59 patients had isolated CCL, without associated extracutaneous symptoms. Histological examination of three CCL showed a lichenoid dermatitis with a perivascular and eccrine mononuclear infiltrate, and vascular microthrombi in 2 cases. Another retrospective study from Spain reported 132 nonhospitalized patients with median age 19.9 (range 1–54 years) and predominantly acral involvement. Mild COVID-19 symptoms preceded skin lesions in 16 patients, with a mean latency time of 9.2 days (range 3–30 days), and in three patients, their onset coincided. The average duration of the skin lesions was 8.7 days (range 2–24 days). Two main patterns of acute ischemic lesions were differentiated: chilblain-like pattern in 95 (72%) patients and erythema multiforme-like pattern in 37 (28%). Acute acral cyanosis in the absence of chilblains has also been seen in an unpublished observation. In contrast to the above-mentioned young and asymptomatic cases, reports from Wuhan described acral ischemia of the lower limbs bilaterally and of solitary fingers of the hands in critically ill COVID-19 patients. Chinese patients, aged above 60, had multiple comorbidities and were hospitalized in the intensive-care unit with severe COVID-19 pneumonia. Hypercoagulopathy, elevated D-dimers, and antiphospholipid antibodies (anticardiolipin IgA, anti-β2-glycoprotein I IgA, and IgG antibodies) in the course of severe infection could explain the presence of ischemic skin lesions. The induced thrombotic events were difficult to differentiate from other causes of multifocal thromboses in critically ill patients, such as disseminated intravascular coagulation (DIC), heparin-induced thrombocytopenia, and thrombotic microangiopathy.

Dengue-like and petechial rashes

Dengue-like rash was reported in a single case from Taiwan, the second country, affected by COVID-19 with 48 patients detected at that time. Neither photographs were made nor skin biopsy was performed since it was not a routine practice according to the dengue clinical practice guideline. The patient further developed respiratory problems and was confirmed COVID-19 positive by real-time PCR. Petechial rash was also observed in Spain, where an 84-year-old woman with arterial hypertension and dyslipidemia was treated with hydroxychloroquine and lopinavir/ritonavir for bilateral COVID-19 pneumonia. Three days after her hospitalization (11 days since the onset of COVID-19 symptoms), she developed slightly pruritic, mostly periaxillary, erythematous-purpuric, coalescing macules. Either the triggering role of the infection itself or the drug intake was discussed.

Livedo-like rashes

Livedo reticularis was reported in two mild COVID-19-positive cases from the USA. Both patients, a 67-year-old man and 47-year-old woman, experienced unilateral, nonpruritic net-like rash which resolved within 19 hours and 20 minutes, respectively. The skin lesions appeared about a week after infection onset and did not reappear on challenge. It was suggested that microthromboses such as in DIC may cause transient livedo in mild-to-moderate COVID-19 cases or acrocyanosis in critically ill patients. Initially, major histological changes were not detected in the skin biopsies of three patients from China, although the presence or absence of skin lesions in these cases was not clearly declared. Later, in three of five critically ill...
SARS-CoV-2-infected patients from the USA presenting with retiform and purpuric lesions, a generalized thrombotic microvascular injury was detected in both pulmonary and cutaneous biopsies. Histological tests from cutaneous lesions and normal-appearing skin revealed a pauci-inflammatory complement-mediated microthrombotic disease with C5b-9 and C4d deposition.59

Androgenetic alopecia

Androgenetic alopecia (AGA) could possibly be related to SARS-CoV-2 infection as both conditions are considered to be androgen mediated.60 Clinically significant AGA was found in 29 (71%) of the 41 Caucasian men with bilateral SARS-CoV-2 pneumonia hospitalized in two tertiary Spanish hospitals. In comparison, the prevalence of AGA among healthy Spanish Caucasian men was estimated at approximately 31–53%.61 Future case-controlled studies may potentially confirm AGA as a predictive factor for increased COVID-19 severity and contribute to the development of antiandrogen therapy for SARS-CoV-2 infection.62

Neonatal rashes

Skin rashes in newborns of COVID-19-infected mothers were reported in two boys out of four infants from China. Maculopapular rash scattered throughout the body was observed in one of the boys who was not tested for SARS-CoV-2. The rash resolved rapidly without treatment and was followed by desquamation. Ulcerated facial skin on the forehead was detected in the other boy who was proven to be SARS-CoV-2 negative. Lesions were quickly followed by diffuse red papules that spontaneously healed within 10 days. None of the four newborns of COVID-19-infected mothers developed disease, and no vertical transmission was detected.63 Kawasaki disease, an acute vasculitis of unknown origin, is another possible but unproven manifestation during COVID-19. It was reported in a 6-month-old, full-term, previously healthy and SARS-CoV-2 positive girl who presented with fever, nonpruritic erythematous maculopapular rash, and other symptoms consistent with classical Kawasaki disease.64

Pigment disorders

Diffuse melanoderma of acute onset was reported from Wuhan in two severely ill Chinese doctors. The exact reason for the observed diffuse skin darkening remained unknown, but hormonal imbalance related to liver dysfunction or drug side effects were suspected, and the changes were considered reversible.65

Classification of the cutaneous manifestations of COVID-19

A prospective nationwide consensus study conducted among dermatologists in Spain summarized clinical data and images of 375 confirmed or suspected COVID-19 cases with cutaneous manifestations. Based on this case collection survey, the authors suggested five cutaneous clinical patterns and several subpatterns associated with COVID-19, as well as few familial clusters. Lesions were classified as acral erythema with vesicles or pustules (pseudo-chilblain) (19%), other vesicular eruptions (9%), urticarial lesions (19%), maculopapular eruptions (47%), and livedo or necrosis (6%). It was also pointed out that the separate types of skin involvement appeared at various points of the disease course and were associated with different duration, severity, and prognosis. This classification might be helpful in recognition of paucisymptomatic patients, epidemiological control, and prognostic evaluation.66

COVID-19 registries

In an online registry launched by the American Academy of Dermatology (AAD) in collaboration with the International League of Dermatological Societies (ILDS), all patients with skin lesions during or following COVID-19 can be reported (Table 2).67 The primary purpose is to rapidly collect dermatologic manifestations

Table 2 International patient registries for dermatological conditions during the COVID-19 pandemic

| Dermatological condition | Patient information | Organization |
|--------------------------|---------------------|--------------|
| Skin diseases in general | https://www.aad.org/member/practice/coronavirus/registry | American Academy of Dermatology |
| Psoriasis vulgaris | https://psoprotect.org/ | Psoprotect |
| Atopic dermatitis | https://www.eczemacouncil.org/news/coronavirus-secure-ad-registry/ | SECURE-Dermatology |
| Autoimmune blistering diseases (AIBD) | https://recovab.umcg.nl | EADV Task Force for AIBD |
| Lupus erythematosus, systemic sclerosis, dermatomyositis (from Europe) | https://www.eular.org/eular_covid19_database.cfm | European League Against Rheumatism |
| Lupus erythematosus, systemic sclerosis, dermatomyositis (outside Europe) | https://rheum-covid.org/ | American College of Rheumatology |
| Hidradenitis suppurativa | https://hs covid.ucsf.edu/ | University of California San Francisco |
| Alopecia areata | https://www.secure-derm.com/secure-alopecia/ | SECURE-Dermatology |

EADV, European Academy of Dermatology and Venereology.
of COVID-19 in order to enable prompt dissemination of the information to the dermatology community and frontline health-care workers. Similar registries based on the submission of downloadable forms have been initiated by the French and Spanish dermatological societies. These registries will certainly help to describe the whole spectrum of COVID-19-related skin changes. Systematic studies on dermatoses during acute COVID-19 may not be expected within the near future and are certainly hampered by the most likely benign course of these skin changes and the lack of involvement of dermatologists in the acute treatment of COVID-19.

Furthermore, disease-specific registries have been initiated, for example, for patients with psoriasis (by PsoProtect), atopic dermatitis (by Secure-AD-registry), connective tissue diseases (by EULAR), and autoimmune blistering diseases (by the corresponding EADV task force) (Table 2).

References

1. Zhang MQ, Wang XH, Chen YL, et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: E013. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0013
2. Guan Wei-jie, Ni Zheng-yi, Hu Yu, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382 (18): 1708-1720. https://doi.org/10.1056/NEJMoa2002032
3. Yan Y, Chen H, Chen L, et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019. Dermatol Ther 2020; 13: e13310. https://doi.org/10.1111/dth.13310
4. Elston Dirk M. Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol 2020; 82(5): 1085-1086. https://doi.org/10.1016/j.jaad.2020.03.012
5. Lan J, Song Z, Miao X, et al. Skin damage and the risk of infection among healthcare workers managing coronavirus disease-2019. J Am Acad Dermatol. 2020; 82: 1215–1216. https://doi.org/10.1016/j.jaad.2020.03.014
6. NICE guideline [NG169] - COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response. https://www.nice.org.uk/guidance/ng169
7. British Association of Dermatologists (BAD) - Advice for Dermatology HCPs [health care professionals] during Covid-19 pandemic. http://www.bad.org.uk/healthcare-professionals/covid-19
8. Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement. Australas J Dermatol 2020; 61: 210-216. https://doi.org/10.1111/ajd.13313
9. Araujo KM, Bressan AL, Azulay-Abulafia L, Zika, chikungunya, and dengue infections as exacerbating factors of psoriasis in patients receiving biological therapy. Int J Dermatol 2020; 59 6: e209-e211. https://doi.org/10.1111/ijd.14785
10. Conforti C, Giufrida R, Dianzani C, et al. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther 2020; 11: e13298. https://doi.org/10.1111/dth.13298
11. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol 2020; 82(5): 1217–1218. https://doi.org/10.1016/j.jaad.2020.03.031
12. Bodemer C, Bauer J, Bolling MC, et al. Patients with rare skin diseases and COVID-19. https://erm-skin.eu/covid-19/
13. Wollenberg A, Flohr C, Simon D, et al. European Task Force on Autoimmune Blistering Diseases (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020; 34: e241-e242. https://doi.org/10.1111/jdv.16411
14. Guidance from the EADV Task Force Autoimmune Blistering Diseases during the COVID-19 pandemic. https://www.eadv.org/covid-19/task-force
15. Kasperkiewicz M, Schmidt E, Fairley JA, et al. Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020; 34: e302-e303. https://doi.org/10.1111/jdv.16525
16. Shakshouk Hadir, Daneshpazhooh Maryam, Murrell Dedee F, Lehman Julia S. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol 2020; 82(6): e235–e236. https://doi.org/10.1016/j.jaad.2020.04.005
17. Arora G, Kassir M, Jafferany M, et al. The COVID-19 outbreak and rheumatologic skin diseases [published online ahead of print, 2020 Mar 31]. Dermatol Ther 2020; 33:e13357 https://doi.org/10.1111/dth.13357
18. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic. Arthritis Rheumatol https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41301
19. Reynolds Sean D, Mathur Anubhav N, Chiu Yvonne E, et al. Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic. Pediatric Dermatol 2020; 37(3): 424–434. https://doi.org/10.1111/pde.14202
20. Frieden Ilona J, Puttgen Katherine B, Drolet Beth A, et al. Management of infantile hemangiommas during the COVID pandemic. Pediatric Dermatol 2020; 37(3): 412–418. https://doi.org/10.1111/pde.14196
21. Der Sarkissian Samuel Antranig, Kim Leo, Veness Michael, Yiassimides Eleni, Sebaratnam Deshan Frank. Recommendations on dermatologic surgery during the COVID-19 pandemic. J Am Acad Dermatol 2020; 83(1): e29-e30. https://doi.org/10.1016/j.jaad.2020.04.034
22. Jakhar D, Kaur I, Kaul S. Art of performing dermoscopy during the times of coronavirus disease (COVID-19): simple change in approach can save the day!. J Eur Acad Dermatol Venereol 2020; 34(6):e242-e244. https://doi.org/10.1111/jdv.16412
23. Royal College of Radiologists - Non-melanoma skin cancer (NMSC) and COVID-19 (PDF). https://www.rcr.ac.uk/sites/default/files/non-melanoma-skin-cancer-covid19.pdf
24. Royal College of Radiologists - Guidelines for follow-up and SACT for melanoma during COVID-19 pandemic (PDF). https://www.rcr.ac.uk/sites/default/files/melanoma-treatment-covid19.pdf
25. Conforti C, Giufrida R, Di Meo N, Zalaudek I. Management of advanced melanoma in the COVID-19. Dermatol Ther 2020; 33(4): e1344. https://doi.org/10.1111/dth.13444
26 Zic John A, Ai Weijun, Akilov Oleg E, et al. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. J Am Acad Dermatol 2020; 83(2): 703–704. https://doi.org/10.1016/j.jaad.2020.04.049

27 Chen Y, Pradhan S, Xue S. What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus? J Am Acad Dermatol. 2020; 82: 1034. https://doi.org/10.1016/j.jaad.2020.02.030

28 American Academy of Dermatology (AAD) - Managing your practice through the COVID-19 outbreak. https://www.aad.org/member/practice/managing/coronavirus

29 Lim Henry W, Feldman Steven R, Van Voorhees Abby S, Gelfand Joel M. Recommendations for phototherapy during the COVID-19 epidemic. J Am Acad Dermatol. 2020; 82: 819–820.

30 Elston DM. The coronavirus (COVID-19) epidemic and patient safety. J Am Acad Dermatol. 2020; 82: 819–820.

31 Chesse H, Chambless JM, Zwemer E. Acute hemorrhagic edema of infancy after Coronavirus infection with recurrent rash. Case Rep Pediatr. 2017; 2017: 5637503. https://doi.org/10.1155/2017/5637503.

32 Schneider H, Adams O, Weiss C, et al. COVID-19 pandemic. Cutaneous Lymphoma Consortium recommendations for biopsies. Clin Dermatol 2020; 38(6):e244–e245. https://doi.org/10.1016/j.clindermatol.2020.04.001

33 Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020; 34(5):e212–e213. https://doi.org/10.1111/jdv.16387

34 Hedou M, Carsuzaa F, Chary E, Hainaut C, Cazenave-Roblot F, Masson Regnault M. Comment on ‘Cutaneous manifestations in COVID-19: a first perspective’ by Recalcati S. J Eur Acad Dermatol Venereol 2020; 34(7):e299–e300. https://doi.org/10.1111/jdv.16519

35 Hunt M, Koziatek C. A case of COVID-19 pneumonia in a young male with full body rash as a presenting symptom. Clin Pract Cases Emerg Med 2020; 4(2):219–221. https://doi.org/10.5811/cpecm.2020.3.47349

36 Hoening LJ, Pereira FA. Rash as a clinical manifestation of COVID19. Photographs of a patient. Clin Dermatol 2020. https://doi.org/10.1016/j.clindermatol.2020.04.001

37 Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol 2020; 34(6):e246–e247. https://doi.org/10.1111/jdv.16471

38 Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol 2020; 34(6):e244–e245. https://doi.org/10.1111/jdv.16472

39 Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jimenez-Cauhe J. Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol 2020; 34(6):e252–e254. https://doi.org/10.1111/jdv.16470

40 Estébanez A, Pérez-Santiago L, Silva E, Guillen-Climent S, García- Vázquez A, Ramón Md. Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol 2020; 34(6):e250–e251. https://doi.org/10.1111/jdv.16474

41 Marzano AV, Genovese G, Fabbrocin G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020; 83(1): 280–285. https://doi.org/10.1016/j.jaad.2020.04.044

42 Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J, et al. Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol 2020. https://doi.org/10.1111/ced.14277

43 Genovesi Giovanni, Colonna Cristiana, Marzano Angelo V. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? Pediatric Dermatol 2020; 37(3): 435–436. https://doi.org/10.1111/pde.14201

44 Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. Dermatol Pediatr. Online ahead of print. https://www.ejpd.com/images/acros ischemia-ENG.pdf

45 Alamthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. Clin Exp Dermatol 2020; 45: 746–748. https://doi.org/10.1111/ced.14243

46 Mazzotta F, Troccoli T, Bonifazi E. A new vasculitis at the time of COVID-19. Eur J Pediatr Dermatol, Monday’s case. https://www.ejpd.com/images/nuova-vasculite-covid-ENG.pdf

47 Kolivras A, Dehavay F, Delplace D, et al. Coronavirus (COVID-19) infection induced chilblains: a case report with histopathological findings. J Am Acad Dermatol Case Rep. 2020; 6: 6489–492. https://doi.org/10.1016/j.jacdcr.2020.04.011

48 Pallier A. ‘COVID Toes’: Mysterious Skin Condition Could be Linked to Coronavirus, Derms Say. Coronavirus Illinois. https://www.nbcchicago.com/news/coronavirus/covid-toes-mysterious-skin-condition-could-be-linked-to-coronavirus-derms-say/2259631/

49 Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol 2020; 34: e291–e293. https://doi.org/10.1111/jdv.16526

50 de Masson A, Bouaziz JD, Sulimovic L, et al. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France. J Am Acad Dermatol 2020. S0190-9622(20)30789-1.

51 Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020; 83(1): e61–e63. https://doi.org/10.1016/j.jaad.2020.04.093

52 Zhang Y, Cao W, Xiao M, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi. 2020; 41: E006. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0006

53 Zhang Yan, Xiao Meng, Zhang Shulan, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020; 382(17): e38. https://doi.org/10.1056/NEJMoa2007575

54 Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31(4): 256–263. https://doi.org/10.1053/sarh.2002.28305

55 Jobb B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82(5): e177. https://doi.org/10.1016/j.jaad.2020.03.036.

56 Jimenez-Cauhe Juan, Ortega-Quijano Daniel, Prieto-Barrios Marta, Moreno-Arrones Oscar M, Fernandez-Nieto Diego. Reply to “COVID-19 can present with a rash and be mistaken for dengue”: Petechial rash in a patient with COVID-19 infection. J Am Acad Dermatol 2020; 83(2): e141–e142. https://doi.org/10.1016/j.jaad.2020.04.016
57 Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol 2020; 83: 700. https://doi.org/10.1016/j.jaad.2020.04.018

58 Yao XH, Li TY, He ZC, et al. Histopathological study of 3 cases of new coronavirus pneumonia (COVID-19) with multi-site puncture. Zhonghua Bing Li Xue Za Zhi. 2020; 49: E009. https://doi.org/10.3760/cma.j.cn112151-20200312-00193

59 Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 5244(20): e1–13. https://doi.org/10.1016/j.trsl.2020.04.007

60 Wambier CG, Goren A. SARS-COV-2 infection is likely to be androgen mediated. J Am Acad Dermatol. 2020; 83: 308–309. https://doi.org/10.1016/j.jaad.2020.04.032

61 Goren Andy, Vano-Galván Sergio, Wambier Carlos Gustavo, et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol 2020; 19(7): 1545–1547. https://doi.org/10.1111/jocd.13443

62 Goren A, McCoy J, Wambier CG, et al. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther 2020; 33(4): e13365. https://doi.org/10.1111/dth.13365

63 Chen Y, Peng H, Wang L, et al. Infants Born to Mothers With a New Coronavirus (COVID-19). Front Pediatr 2020; 8(104). https://doi.org/10.3389/fped.2020.00104

64 Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020; 10(6): 537–540. https://doi.org/10.1542/hped.2020-0123

65 Steinbuch Y. Chinese doctors’ skin turns dark after coronavirus recovery. April 21, 2020, New York Post. https://nypost.com/2020/04/21/chinese-doctors-skin-turns-dark-after-coronavirus-recovery/

66 Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71–77. https://doi.org/10.1111/bjd.19163

67 Freeman EE, McMahon DE, Fitzgerald ME, et al. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19. J Am Acad Dermatol 2020; 83: 509–510. https://doi.org/10.1016/j.jaad.2020.04.045

© 2020 the International Society of Dermatology International Journal of Dermatology 2020, 59, 1312–1319